Changes in Beneficial Ownership · 4
IGC Pharma, Inc.
IGCNYSE_AMERICANEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-06-30
- Issuer
- IGC Pharma, Inc.
- Issuer CIK
- 0001326205
- Trading symbol
- IGC
Reporting owner 1
- Name
- Mukunda Ram
- Reporting owner CIK
- 0001047575
- Relationship
- Director · Officer
- Officer title
- CEO
- Address
- 10224 FALLS ROAD, POTOMAC, MD, 20854
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-06-30 | A · Form 4 | 2,226,475[F1] | A | 0.27 | 6,875,563 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Shares of common stock acquired directly from the Issuer in a private placement in exchange for cancellation of $601,148 of outstanding indebtedness owed by the Issuer to the Reporting Person. The shares were issued at $0.27 per share, are restricted securities within the meaning of Rule 144, and were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. The transaction was approved in advance by the disinterested directors and the Audit Committee, with the Reporting Person recused, for purposes of Rule 16b-3.↩ 1
Signature 1
- Signed
- /s/ Ram Mukunda
- Date
- 2026-06-30
Company context
IGC Pharma (NYSE American: IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer’s dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With more than 30 patent filings, 12 patents granted and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.